



*The Original HHP*

**SUMMARY CHART OF HERPES & HPV RESEARCH**

INFORMATION AS OF 8/1/2005

COMPANY (website)	Affiliations	PRODUCT	TYPE OF PRODUCT (P) - Prophylactic (T) - Therapeutic (Rx) - Treatment	STAGE OF DEVELOPMENT	DATE MOST RECENT NEWS (SOURCE)	MISC NOTES
-------------------	--------------	---------	--	----------------------	--------------------------------	------------

**Vaccines**

1) <b>Antigenics</b> New York (www.antigenics.com)	University of Washington, Westover Heights, Fred Hutchinson Cancer Research Center	<b>AG702/AG707:</b> recombinant human heat shock protein to induce T cell response	(P)&(T) vaccine for HSV2 // a monovalent vaccine	<b>AG-707:</b> FDA IND submitted (usually 30 day turnaround) // recruitment of 84 subjects for a multisite Phase I scheduled to begin by end of 2005	3/17/2005 - <b>AG-702</b> info: muffin phone call with Westover Heights <b>AG-707</b> info from company website February 2005 webcast & correspondence with AGEN Communications Dept <b>3/31/2005:</b> Annual Report 2004 <b>7/28/2005:</b> Antigenics webcast/company website news release	Company Website: AG707 clinical trial anticipated 2005 // Info re: AG702/AG70x: <a href="http://www.antigenics.com/news/factsheets/ag70x.pdf">http://www.antigenics.com/news/factsheets/ag70x.pdf</a> // Development of AG 702 has ceased, proceeding with AG707
2) <b>AuRx, Inc.</b> Maryland (www.aux.com) Contact: Gary Calton (President)		<b>Theraherp (aka ICP10?PK aka Delta PK)</b>	(T) recombinant vaccine genetically attenuated	pre Phase III	10/3/2004 - company website	<b>11/4/2004:</b> Company needs \$ in order to progress (email to HHP member) <b>2/2005:</b> lining up funding source rumored on IHUB w/ Phase III to begin in 6 months (per email from Dr Calton to Newbie)
3) <b>AusAm Biotechnologies</b> New York (www.ausambiotech.com)	collaborating with NIH	<b>DES6</b>	(T) :broadpectrum antiviral therapeutic for herpes, HIV & small pox	preclinical - scheduled for human trials late 2003		
4) <b>AVANT Immunotherapeutics</b> Massachusetts (www.avantimmune.com)	Harvard Medical School (Dr Kriple), NIH (Dr. Strauss)	<b>dl5-29</b>	(P) and (T) vaccine for HSV2	Preclinical results indicate they are ready to proceed to human trials	<a href="http://www.eurekaalert.org/pub_releases/2004-12/hms-soe121404.php">12/14/2004 - www.eurekaalert.org/pub_releases/2004-12/hms-soe121404.php</a>	2000 AVANT press release: they have exclusive worldwide rights to Harvard patent // 11/5/2004: AVANT press release opened vaccine manufacturing facility in Fall River, MA // 1/9/2005: Dr Kriple awarded 5 year NIH grant
<b>BioVex</b> (www.biovex.com)		<b>ImmunoVEX hsv2</b>	(P) vaccine for HSV2 and possible reduction of shedding	Preclinical // Phase I anticipated in 2006	4/22/2005 - company website	8/3/2005: announcement of preclinical results expected to be announced (thanks Anonymous!) per company websites
5) <b>BioVirus Research Inc</b> (BioVirus Medical) Nevada Tekron contact: Dr. James Insell (519)433-4400	Tekron, Inc // Tekron & BioVirus to form Canadian subsidiary of BioVirus	<b>Universal Peptide Herpetic Vaccine</b> (www.virology.net/garry/favwebvacc.html)	several (P) and (T) synthetic peptide vaccines from viral genomes for HSV1 and HSVII		11/4/2003 - Yahoo! Finance 11/12/2003 - PrimeZone.com	veterinary applications as early as spring 2005
6) <b>Cytogenix, Inc.</b> Texas (www.cytogenix.com)	10/1/2004: Affiliation with Phanuel Pursuits failed	<b>Simplivir (aka CY301)</b> anti herpes cream for HSV1 or HSV2 to strip virus from being able to migrate to the nerve cell	(T) topical treatment CY301 (P) & (T) vaccine	preIND teleconference w/ FDA Jan 18, 2005	11/4/2004 - <a href="http://biz.yahoo.com/bw/041104/45128_1.html">http://biz.yahoo.com/bw/041104/45128_1.html</a> // 12/29/2004 - Press Release letter from President // 2/21/2005 - IHUB website re: court case	targetting End of 2005 to begin Phase I (company website) // per IHUB website: court trial vs. Phanuel Pursuit
6) <b>Cytogenix, Inc.</b> Texas (www.cytogenix.com)	10/1/2004: Affiliation with Phanuel Pursuits failed	<b>CY501</b>	(T)	Pre-Clinical	4/2005 - company website	
8) <b>Henderson Morley</b> Birmingham, England (www.henderson-morley.com)	HM is a discovery company seeking partner(s) to take products into clinical development	(1) <b>ICVT therapy</b> (2) <b>Intracellular Herpes vaccine</b> (Skinner vaccine) (3) <b>Prep vaccine</b>	(1)topical (2) Skinner: (P) & (T) vaccine (3) Prep: (T) vaccine	Pre-Clinical	10/2004 - Company website <b>Science</b> (3) Preps: <a href="http://www.henderson-morley.com/main/preps_vaccine_rational.html">http://www.henderson-morley.com/main/preps_vaccine_rational.html</a>	Skinner may be available as part of "Named Patient program". Register on co website: <a href="http://www.henderson-morley.com/main/contact_us.html">http://www.henderson-morley.com/main/contact_us.html</a>

	John Hopkins School of Public Health Dr. Paul Ts / Laure Aurelian		(P) & (T) vaccine	Preclinical	7/30/2005: <a href="http://www.jhsph.edu/TechTransfer/Industry/inventions.html">http://www.jhsph.edu/TechTransfer/Industry/inventions.html</a>	available for licensing
9)	Lund University Sweden	Cystapep	(T)	preclinical research	12/2003 - <a href="http://www.eurekalet.org/pub_releases/2003-12/src-nwt121003.php">http://www.eurekalet.org/pub_releases/2003-12/src-nwt121003.php</a>	
	MedImmune Vaccines Inc. (California)	AD472	(P) & (T) GHSV2	Pre-Clinical	3/19/2005 Abstract from Journal article in <i>Vaccine</i>	did not prevent infection or virus replication in the vaginal tract, but did reduce both lesion development and severity in a dose-dependent manner in guinea pigs
	NanoViricide <a href="http://www.nanoviricide.com">http://www.nanoviricide.com</a>	6/2005 Edot.com acquires Nanoviricide // science licensed from Theracour Pharma		Preclinical		
	Northwestern University		(T) HSV1 & HSV2	Preclinical	7/30/2005: <a href="http://ftp.northwestern.edu/abstracts/viewabs.php?id=243&amp;cat=127">http://ftp.northwestern.edu/abstracts/viewabs.php?id=243&amp;cat=127</a>	available for licensing
10)	PowderMed Oxford, England (www.powdermed.com)	Chiron // PowderJect	PMED (aka DNA on gold; originally PowderJect) DNA mediated epidermal delivery induces both humoral and cellular immunity	(P) and (T) vaccines for HSV2	Phase I clinical trial on humans in Houston, TX for approx 8 months // enrollment full	12/21/2004 - CCSTexas
	REPLICor Montreal (www.replicor.com/index.htm)	McGill University // seeking partners	REP 9	(T)	Preclinical	3/30/2005 - company website press release
11)	Xenova (www.xenova.org)	looking for Global partner	DISC-Pro	(P) vaccine	poised for Phase III	5/27/2003 - <a href="http://www.smallcapmarketwatch.com">www.smallcapmarketwatch.com</a> // 4/2005 - company website DISC-Pro: seeking partner // listed on their list of De-prioritized Programs (per company website)
12)	University of Florida Vical	looking for partner/funding UW, NIH		(T) vaccine (T) vaccine for HSV2	Preclinical Preclinical	NIH grant issued to Dr Koelle at Uwash for 4/4005 - 11/2005

## Treatments

	Adventrix Pharmaceuticals (www.adventrx.com)	NIH	Thiovir // thioanalogues	(Rx)	Preclinical	7/30/2005 - company website	being studied right now for HIV but has shown efficacy against herpes (thanks Anonymous!)
1)	Bayer (Germany) (www.bayer.com)	Dr Kleymann (University of Tübingen)	BAY 57-1293 (Helicase inhibitor) against HSV1 and HSV2	(Rx)	Preclinical	11/2004 - company website	Bayer brochure: <a href="http://www.research.bayer.com/medien/pages/2999/herpes.pdf">http://www.research.bayer.com/medien/pages/2999/herpes.pdf</a>
2)	Boehringer Ingelheim Ltd (Canada)		BILS 175 BS (Helicase inhibitor) against HSV1 and HSV2	(Rx)	Pre-clinical	12/2004 - Antiviral Res. 2004 Dec;64(3):161-70.	
3)	CEL-SCI Vienna, VA		CEL 1000 (aka derG)	(Rx) for GHSV peptide w/ strong immunity stimulatory action incl induction of protective immune responses	Phase I/II animal studies	9/2002 - <a href="http://www.bioinfo.com">www.bioinfo.com</a> Antiviral Agents Database / (company website)	Science behind LEAPS: <a href="http://www.cel-sci.com/leaps.htm">www.cel-sci.com/leaps.htm</a> // gov't funding for CEL1000 technology research
4)	Flamel Technologies France (www.flamel-technologies.fr)	4/2003: licensed to BioVail for manufacturing and marketing in US and Canada // 3/5/2005: relation with Biovail terminated for lack of progress on Biovail's part // Flamel is seeking new partner // 4/2005 (company website) In discussions with potential corporate partners	Genvir (acyclovir pro-drug) controlled release acyclovir	Rx of acute gHSV	Phase III completed in Europe // Phase III in US to anticipated to begin end of 2004	4/2004 - Flamel annual SEC filing // <a href="http://ir.10kwizard.com/filing.php?repo=tenk&amp;page=2748465&amp;doc=1&amp;num=26&amp;total=123&amp;source=331&amp;f=24">http://ir.10kwizard.com/filing.php?repo=tenk&amp;page=2748465&amp;doc=1&amp;num=26&amp;total=123&amp;source=331&amp;f=24</a> // 3/5/2005: <a href="http://biz.yahoo.com/ap/050303/flamel_biovail_1.html">http://biz.yahoo.com/ap/050303/flamel_biovail_1.html</a>	Pricing to be below that of other prodrugs

5)	<b>GlaxoSmithKline (GSK)</b> (www.gsk.com)		<b>Valtrex XR</b>	(Rx) GHSV	Phase I	10/3/2004 - company website	
	<b>Kent State University</b>	Docherty, Tsai	Tolan compounds	(Rx)	Preclinical	7/30/2005: Page 8 on <a href="http://www.techtrans.kent.edu/AvailableTechnologiesBook.pdf">http://www.techtrans.kent.edu/AvailableTechnologiesBook.pdf</a>	
6)	<b>Medivir</b> Sweden (www.medivir.se)	seeking partner to out license Phase III	<b>ME-609</b> (topical acyclovir)	prevents/suppresses cold sores	preparing for Phase III	9/2004 - company website 4/2005 - Annual Report 2004	potential GHSV indication later
7)	<b>Medivir</b> Sweden (www.medivir.se)	seeking partner to out license Phase III	<b>MIV-606</b>	(Rx) reduces pain of shingles	preparing for Phase III	11/7/2004 - company website 4/2005 - Annual Report 2004	potential GHSV indication later
	<b>NanoBio Corporation</b> (www.nanobio.com)		<b>NB-001</b>	(Rx) for cold sores	Phase II completed - Phase III to begin 2006	7/21/2005: company press release	Findings: A significant proportion of subjects on the highest dose of NB-001 had healing two or more days earlier than the control group.
		available for licensing	<b>NB-004</b>	(Rx) topical for hsv2	poised to enter Phase II	7/30/2005 - company website	
8)	<b>Novactyl</b> Louis, MO	St. Upper-Smith Laboratories, Inc.	<b>PCL-016 &amp; FSR488</b>	(Rx) oral & genital HSV; topical // both target ZincFinger Proteins	Phase II (PCL-016)	9/2002 - www.bioinfo.com under Antiviral Agents Bulletin	
9)	<b>Royalmount Pharmaceuticals</b> Canada		<b>Resveratrol</b>	(Rx) and (P)	preclinical - anticipates clinical trials ???		Found by reallyworried
10)	<b>Transport Pharmaceuticals</b>	Nexus Therapeutics	acyclovir (40 times stronger than usual)	(Rx) cold sore	Phase II completed. Progression to Phase III in 2005	11/22/2004 - <a href="http://biz.yahoo.com/prnews/041122/nem013_1.html">http://biz.yahoo.com/prnews/041122/nem013_1.html</a>	

### Microbicides/Prevention

1)	<b>AusAm Biotechnologies</b> New York (www.ausambiochem.com)	collaborating with NIH	<b>DES10</b>	prevention	preclinical	2/24/2004 - press release on company website	
2)	<b>Cellegy Pharmaceuticals, Inc.</b> San Francisco, CA (www.cellegy.com)	acquired Biosyn 10/8/2004 // Family Health International, US Agency for International Development, CONRAD	<b>Savvy (aka C31G)</b>	prevention	2 Phase III studies in Africa (Ghana on 5/20/2004 & Nigeria); 10/2004 Phase III contraceptive study initiated in US Anticipated duration 12-36 months // Fast-track status by FDA on 11/17/2003 // 3/3/2005: 50% enrollment achieved	10/8/2004 - press release on company website // 12/2004 - company website: <a href="http://www.cellegy.com/products/savvy.html">http://www.cellegy.com/products/savvy.html</a> // 3/3/2005: <a href="http://www.biospace.com/news_story.cfm?StoryID=19262820&amp;full=1">http://www.biospace.com/news_story.cfm?StoryID=19262820&amp;full=1</a>	primary indication is for HIV but anticipates HSV and HPV indication // 12/2004: <a href="http://www.cellegy.com/products/savvy.html">http://www.cellegy.com/products/savvy.html</a> ...studies to be completed by 2nd half of 2006 with NDA filing anticipated early 2007 //
3)	<b>GlaxoSmithKline (GSK)</b> (www.gsk.com)	Corixa	Herpevac study of <b>Simplirix</b>	(P) vaccine for GHSV in women w/o HSV1 or HSV2	Phase III (4 year trial started abt 1/2003)	12/10/2003 - Corixa website	at least the 2nd Phase III trial // 12,000 volunteers in trials thus far
	<b>Harvard Medical School</b>	Judy Lieberman	long lasting gel using small interfering RNAs	extended prevention	Pre clinical	4/30/2005 - <a href="http://news.bbc.co.uk/2/hi/health/4483155.stm">http://news.bbc.co.uk/2/hi/health/4483155.stm</a>	
4)	<b>Indevus Pharmaceuticals</b> (www.indevus.com)	licensed from Procept, Inc.	<b>PRO2000</b> using 2-naphthalene sulfonic acid formaldehyde condensate, sodium salt - fractionated	prevention	entering Phase II/III // commencing recruitment for 30 month study in Africa & Philadelphia	2/11/2005 - company website	2/24/2005: demonstrating effectiveness against herpes!!! <a href="http://www.betterhumans.com/News/news.aspx?articleID=2005-02-24-3">http://www.betterhumans.com/News/news.aspx?articleID=2005-02-24-3</a>
5)	<b>Global Microbicide Project</b> (Virginia) (www.gmp.org) <b>Inc.</b> www.softcup.c	Rush-Presbyterian-St.Luke's Medical Center <b>Instead,</b>	<b>Amphora (aka Acidform)</b>	prevention and contraceptive	Phase I in US, Brazil and India	10/30/2004 - company website - NewsLink // <a href="http://quickstart.clari.net/qs_se/webnews/wed/aw/Bca-Instead.RTRx_DIP.html">http://quickstart.clari.net/qs_se/webnews/wed/aw/Bca-Instead.RTRx_DIP.html</a>	
6)	<b>Polydex Pharmaceuticals</b> Canada (www.polydex.com)	Toronto, CONRAD, TOPCAD, CICCRR	<b>Ushercell</b> (aka Cellulose sulfate)	prevention	Phase III trial for HIV and other STD prevention (incl hsv1 & hsv2) in Africa (began January 2004)	10/19/2004 - <a href="http://www.polydex.com/v2/news/04-10-19.html">http://www.polydex.com/v2/news/04-10-19.html</a>	11/15/2004: email from Gary Usher to goodgirl...the strategy is to get the product to market ASAP possible via a Bactrial Vaginosis indication
7)	<b>Population Council</b> New York (www.popcouncil.org/biomed/candidate.html)	Univ of Cape Town, Medical Univ of Southern Africa, Medical Research Council	<b>Carraguard</b> (aka PC-515)	prevention *kills virus without killing sperm so user can become pregnant	Phase III March 2004 for 3 years in Africa	9/1/2004 - company website	primary indication is for HIV but kills HSV and HPV in lab tests in vivo and in vitro
8)	<b>ReProtect, Inc</b> Maryland (www.reprotect.com)	NIH , NIAID, FHI	<b>BufferGel</b>	prevention	<b>Trial for HPTN-035</b> (for HIV, HSV, BV & other stds) Phase II/III starting November 2004, anticipated 30 month duration in Africa <b>Trial CCN-003</b> (for contraception) Phase III ending mid 2004	10/14/2004 - <a href="http://www.hptn.org/research_studies/HPTN035.asp">http://www.hptn.org/research_studies/HPTN035.asp</a>	primary indication is for HIV but kills HSV and HPV in lab tests in vivo and in vitro // being tested with PRO2000 // 12/11/2004: <a href="http://www.wsvn.com/features/articles/medicalreports/D8M852/">http://www.wsvn.com/features/articles/medicalreports/D8M852/...</a> "could be on the market in a year or two"
9)	<b>Starpharma</b> Melbourne, Australia (www.starpharma.com)		<b>VivaGel</b> (aka SPL7013) topical micobicide (vaginal gel) for women to protect themselves against HIV and other STDs including HSV	prevention *kills virus without killing sperm so user can become pregnant	Phase I human safety study successfully completed	12/15/2004 - company website press release	target market date mid2007

University of Texas - Dr Simmons

(P) prevention G HSV1 & possibly HSV2    Preclinical    [http://research.utmb.edu/web\\_brochures/Therapeutics-Biotechnology/Topical%20Microbicide%20for%20Prevention%20of%20Herpes%20Infections.pdf](http://research.utmb.edu/web_brochures/Therapeutics-Biotechnology/Topical%20Microbicide%20for%20Prevention%20of%20Herpes%20Infections.pdf)

## Adjuvants

1) <b>AlphaVax</b> Research Triangle Park, NC (www.alphavax.com)	Wyeth-Lederle Vaccine & Pediatrics division in 1998	<b>ArV</b> (AlphaVax Replicon Vector) Vaccine Packaging System //adjuvant to improve preventative and therapeutic vaccines	(P) and (T) vaccines	Phase I began in 2003	7/20/2005: Vaccine Weekly article	7/20/2005: "The company is working with a number of other academic and industry partners on vaccines for disease like herpes"
2) <b>Avantogen</b> (used to be Australian Cancer Technology) Australia (www.avantogen.com)	University of Alabama	GPI - 0100	(T) adjuvant originally used in HSV vaccine by Galenica	Pre-Clinical	6/15/2005: <a href="http://www.rednova.com/news/display/?id=156218&amp;source=f_health">http://www.rednova.com/news/display/?id=156218&amp;source=f_health</a>	
3) <b>Corixa Corp.</b> (www.corixa.com)	GSK, BioSante, Fred Hutchinson; UWashington // see GSK above)	<b>MPL adjuvant</b> used in GSK Simplrix	MPL in combo with GSK vaccine increases immune response to antigens in vaccine	Pre-Clinical research on BioSantes' BioVant	11/6/2004 - company website	

## Failed Trials

<b>Chiron</b>		gD2 gB2 vaccine // <b>MFS9</b>	vaccine	failed Phase III presumably because of adjuvant		Chiron is now affiliated with PowderMed
<b>Eli Lilly</b>	3M	<b>Resiquimod</b> : immune modulator to facilitate endogenous vaccination increasing cell mediated immunity to endogenous HSV2 antigens	(Rx) topical gel to decrease frequency of OBs for GHSV2	failed Phase III - ineffective, did not see significant results (2/24/2003)	2/24/2003 - <a href="http://www.healthscout.com/status/news/1500928.html">www.healthscout.com/status/news/1500928.html</a>	Collaboration with 3M terminated
<b>ML Laboratories</b> UK (www.mllabs.co.uk)		<b>Emmelle Gel</b>		ML Labs stopped all activity when it was determined that Emmelle is not as effective as PRO2000.	9/9/2004 - press release (company website)	primary indication is for HIV but anticipates HSV and HPV indication
<b>Xenova</b>	GSK	<b>TA-HSV</b>	vaccine	failed Phase II	10/21/2001	<a href="http://www.xenova.co.uk/pdfs/XenovaPrelim02.pdf#search=TA%20HSV">http://www.xenova.co.uk/pdfs/XenovaPrelim02.pdf#search=TA%20HSV</a>

## Keep an eye on...

<b>BioSante Pharmaceutical</b> (www.biosantepharma.com)	Army, navy, NIH, CDC, Corixa, DynPort	<b>BioVant CAP</b> adjuvant delivery system using calcium phosphate	BioVant combined w/HSV2 antigens to increase immune response to antigen	Pre-clinical	4/29/2004 - <a href="http://www.homelanddefensestocks.com">www.homelanddefensestocks.com</a> // company website press releases	current research focussing on ricin, anthrax, malaria
<b>Dynavax</b> (www.dynavax.com)		<b>ISS</b> stimulates innate immune system for use in (p) and (t) vaccines	adjuvant?	Preclinical	company website	current research focusing on small pox and anthrax
5) <b>Roche</b> Nutley, NJ	Stressgen	<b>R1461</b> (CoVal Fusion Protein)	adjuvant for vaccine	Pre-Clinical for HSV application		technology may transfer to HSV but they are focusing research on HPV currently

## MISC Companies

Apollon (see Wyeth-Lederle)

**Aviron** (see MedImmune Vaccine, Inc.)    **RAV9395**    [www.bioinfo.com](http://www.bioinfo.com) (Antiviral Agents Bulletin database)    2/2002:acquired by MedImmune Vaccine, Inc.

**Australian Cancer Technology**    5/31/2005 named changed to Avantogen

**Biosyn** (see Cellergy)

**BioVail**    failed partnership with Flamel Technologies // 3/5/2005: Flamel terminated agreement for lack of progress on Biovail's part    **Genvir** (acyclovir pro-drug)

**Cantab** (see Xenova)

**Chiron** (see PowderMed)    5/20/2003: acquired PowderJect

**Galenica Pharmaceuticals** (see Australian Cancer Technology)    5/17/2004: created PowderMed  
6/23/2004 Australian Cancer Technology acquired Galenica Pharmaceuticals

**VRI, Inc.** (see Avant Immunotherapeutics)    5/1998 VRI, Inc. became Avant Immunotherapeutics

## HPV

<b>3M</b>	Takeda Pharmaceutical Company (Japan)		(Rx) topical for high risk HPV & Cervical dysplasia	Phase I	3/3/2005 - <a href="http://www.pharmabiz.com/article/detnews.asp?articleid=26474">http://www.pharmabiz.com/article/detnews.asp?articleid=26474</a> 4/29/2005 - GSK press release	
<b>Corixa Corp.</b> Seattle, WA (www.corixa.com)	see GSK // GSK acquires Corixa effective 3rd quarter 2005					
<b>GlaxoSmithKline (GSK)</b> (www.gsk.com)	Corixa (acquires Corixa effective 3rd quarter 2005)	<b>Ceravix</b>	(P) vaccine for HPV16 and HPV18	Phase III (2 studies planned enrolling 25,000 women to begin in 2004)	12/10/2003 - company website	Phase II demonstrated 100% effectiveness in preventing persistent infection // has potential to prevent 70%+ of cervical cancers goal to start trials in 2006
<b>Innogenetics</b>		<b>HPV Polytope vaccine</b>	(T) for HPV 16, 18, 31, & 45	Preclinical	11/2004 - company website	
<b>MediGene</b>		<b>Polyphenon E</b>	(Rx) genital warts - elimination of an reduced recurrence rate	Phase III completed - applying for FDA approval in 2005	12/15/2004 - <a href="http://www.bioworld.com/server/com.accumedia.web.Dispatcher?next=bioworldheadline_s_article&amp;forceid=34268">http://www.bioworld.com/server/com.accumedia.web.Dispatcher?next=bioworldheadline_s_article&amp;forceid=34268</a>	
<b>Merck</b>	UWashington	<b>Gardasil</b>	(P) vaccine for HPV16 and HPV18	Phase III	11/1/2004 - <a href="http://www.cnn.com/2004/HEALTH/conditions/11/01/cancer.vaccine.ap/index.html">http://www.cnn.com/2004/HEALTH/conditions/11/01/cancer.vaccine.ap/index.html</a>	3 doses over 6 months // a little further ahead in development than GSK
<b>MGI Pharma</b>		<b>ZYC101A</b> for patients with cervical dysplasia	(T) for HPV16 & HPV18	Phase III to begin in 2005	12/9/2005 - company website, 4th Quarter SEC report	
<b>Novavax</b> Columbia, MD			(T) vaccine	Preclinical	11/2004 - company website	
<b>PowderMed</b>			(T) vaccine for genital warts+E16	Preclinical ongoing (anticipates going to trials in 1-2 years)	4/2005 - company website	
<b>SciClone Pharmaceuticals, Inc.</b>	Verta Ltd (Russia)	<b>SCV-07</b>	(T) or (Rx) of HPV lesions	Phase I to begin in 2005 // Phase II in 2006	7/25/2005: company press release	
<b>Stressgen</b> BC, Canada (250)744-2811 San Diego (858)202-4900 (www.stressgen.com)	ROCHE	<b>HspE7</b> for HPV and RRP (respiratory HPV) * has fast-track status // also researching effectiveness for internal genital warts and women with cervical dysplasia		Phase II for warts and HPV16	11/2004 and 12/2004 press releases on company website	patent issued for HspE7 for RRP until 2021 // Phase II data analysis expected to be complete mid- to end of 2005 // for the science behind it: <a href="http://www.stressgen.com/product/index.htm">www.stressgen.com/product/index.htm</a>
<b>Transgene</b>		<b>MVA HPV IL2</b>	(T) for HPV16 & HPV18	2nd Phase II beginning (France)	11/30/2004 - company website press release <a href="http://www.transgene.fr/us/pdf/communique_presse/communiqués_divers_2004/PR-US_HP_V30-11-2004.pdf">http://www.transgene.fr/us/pdf/communique_presse/communiqués_divers_2004/PR-US_HP_V30-11-2004.pdf</a>	data from 2nd Phase II expected end of 2005
<b>Xenova</b>	Cancer Research Technologies Ltd.	<b>TA-CIN</b> for women with cervical dysplasia	(Rx)	2nd Phase II beginning in 2005 (20-30 women in UK)	1/10/2005 - company website	